CN109464587A - 一种治疗高血压的口服液 - Google Patents
一种治疗高血压的口服液 Download PDFInfo
- Publication number
- CN109464587A CN109464587A CN201811365006.3A CN201811365006A CN109464587A CN 109464587 A CN109464587 A CN 109464587A CN 201811365006 A CN201811365006 A CN 201811365006A CN 109464587 A CN109464587 A CN 109464587A
- Authority
- CN
- China
- Prior art keywords
- selenium
- pomace
- rich
- hypertension
- oral solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 41
- 229940100688 oral solution Drugs 0.000 title claims abstract description 30
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000011669 selenium Substances 0.000 claims abstract description 49
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 49
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 21
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000811 xylitol Substances 0.000 claims abstract description 21
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 21
- 235000010447 xylitol Nutrition 0.000 claims abstract description 21
- 229960002675 xylitol Drugs 0.000 claims abstract description 21
- 235000019774 Rice Bran oil Nutrition 0.000 claims abstract description 20
- 239000008165 rice bran oil Substances 0.000 claims abstract description 20
- 239000008159 sesame oil Substances 0.000 claims abstract description 18
- 235000011803 sesame oil Nutrition 0.000 claims abstract description 18
- 235000012907 honey Nutrition 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 54
- 229940079593 drug Drugs 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000009835 boiling Methods 0.000 claims description 10
- 240000006053 Garcinia mangostana Species 0.000 claims description 8
- 235000017048 Garcinia mangostana Nutrition 0.000 claims description 8
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 8
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 8
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 8
- 235000021014 blueberries Nutrition 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 7
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 7
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 7
- 235000004634 cranberry Nutrition 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 6
- 239000008155 medical solution Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 239000005361 soda-lime glass Substances 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 241000234435 Lilium Species 0.000 claims description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 5
- 241000180649 Panax notoginseng Species 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 235000013325 dietary fiber Nutrition 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000002002 slurry Substances 0.000 claims description 5
- 244000046146 Pueraria lobata Species 0.000 claims description 4
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 4
- 238000013329 compounding Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 18
- 208000024891 symptom Diseases 0.000 abstract description 9
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 description 14
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 240000004308 marijuana Species 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910001608 iron mineral Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种治疗高血压的口服液，由以下成分组成：御米油75‑100g，火麻油5‑15g，富硒果渣1‑8g，蜂蜜1‑5g，木糖醇适量。本发明结合御米油、火麻油和富硒果渣可以有效的治疗高血压症状，且安全无毒副作用。
Description
技术领域
本实用发明涉及医药领域，特别涉及一种治疗高血压的口服液。
背景技术
高血压（hypertension）是指以体循环动脉血压（收缩压和/或舒张压）增高为主要特征（收缩压≥140毫米汞柱，舒张压≥90毫米汞柱），可伴有心、脑、肾等器官的功能或器质性损害的临床综合征。高血压是最常见的慢性病，也是心脑血管病最主要的危险因素。正常人的血压随内外环境变化在一定范围内波动。在整体人群，血压水平随年龄逐渐升高，以收缩压更为明显，但50岁后舒张压呈现下降趋势，脉压也随之加大。近年来，人们对心血管病多重危险因素的作用以及心、脑、肾靶器官保护的认识不断深入，高血压的诊断标准也在不断调整，目前认为同一血压水平的患者发生心血管病的危险不同，因此有了血压分层的概念，即发生心血管病危险度不同的患者，适宜血压水平应有不同。
血压值和危险因素评估是诊断和制定高血压治疗方案的主要依据，不同患者高血压管理的目标不同，医生面对患者时在参考标准的基础上，根据其具体情况判断该患者最合适的血压范围，采用针对性的治疗措施。在改善生活方式的基础上，推荐使用24小时长效降压药物控制血压。除评估诊室血压外，患者还应注意家庭清晨血压的监测和管理，以控制血压，降低心脑血管事件的发生率。
目前常用的降压西药有卡托普利、硝苯地平、氢氯噻嗪等药物，这些药物疗效确切，服用方便，但副作用大、价格昂贵、必须长期服药，而且容易产生抗药性而出现反复发作的缺点，由于传统中医药具有强调整体观念、协调阴阳、标本兼治、毒副作用小等优点，它不仅可以有效控制血压，还可以预防并发症及保护脏器，起到标本兼职的目的。但是，目前临床上缺乏有效的降压中成药。
发明内容
本实用发明为了一种治疗高血压的口服液，克服了西药依赖性强、副作用大及现有的中药治愈效果差、周期长的缺点。
本实用发明是通过如下技术方案实现的：
一种治疗高血压的口服液，由以下成分组成：御米油75-100g，火麻油5-15g，富硒果渣1-8g，蜂蜜1-5g，木糖醇适量。
优选地，御米油87g，火麻油10g，富硒果渣2g，蜂蜜1g，木糖醇适量。
本发明的治疗高血压的口服液，所述富硒果渣是由富硒蓝莓果渣20-25份、富硒蔓越莓果渣10-15份、富硒山竹果渣15-20份制备而成。
本发明的治疗高血压的口服液，所述所述的富硒果渣的制备方法：将富硒蓝莓、富硒蔓越莓、富硒山竹果渣加入到粉碎机中，然后加入药物提取液，药物提取液与混合果渣的重量比为2:1，然后进行湿法超微粉碎，粉碎时间10-20分钟，转速12000rpm，物料粒度下降到200微米以下；然后对果渣浆进行真空浓缩。
本发明的治疗高血压的口服液，所述的药物提取液的制备方法为：提取液是由葛根、丹参、枸杞、三七、百合以及黄芪按照质量比3：2：2：4：2：1复配后水提而成。
本发明的治疗高血压的口服液，所述药物提取液的制备方法为：将提取物的原料药加入10倍的水，浸泡2小时，煮沸后保持沸腾状态20分钟，经过100-200目筛过滤得滤液；将残渣再加入6倍的水，煮沸后保持沸腾状态30分钟，经100-200目筛过滤得滤液，将两次滤液合并，真空浓缩至原来的1/2，冷却后得到药物提取液。
本发明的治疗高血压的口服液的制备方法，将御米油、火麻油、富硒果渣、蜂蜜和木糖醇放入容器内充分搅拌混合，搅拌器转数为 400r/min，然后加入木糖醇，得混合药液；用氢氧化钠溶液调节 pH值至6.8，再灌封至钠钙玻璃管制口服液瓶中，灌装轧盖后置于98℃条件，灭菌15min，入库即为成品，即得治疗高血压的口服液。
火麻油又叫大麻仁或麻仁，为桑科植物大麻的干燥成熟果实。其味甘、性平，入脾、胃，能润燥滑肠，滋养补虚。火麻仁含有丰富的蛋白质、不饱和脂肪酸，还有卵磷脂、亚麻酸、维生素及钙、铁矿物等人体必需的微量元素。食之有润肠胃、滋阴补虚、助消化、明目保肝、祛病益寿之功效，且对便秘、高血压和高胆固醇等疾病有特殊的疗效，而且火麻是唯一能够溶于水的油料。
御米油是采用物理压榨工艺而制成的一种含有极高复合营养成份的纯天然珍稀绿色食用植物油。御米油含有人体正常生长所必需的多种脂肪酸和十余种氨基酸，以及铜、硒、镁、铁、锌、锰等多种微量元素。其中亚油酸（含量高达68%以上）与亚麻酸等多不饱和脂肪酸是人体必需却又不能自行合成的必需脂肪酸，因此御米油的主要营养作用有：提高睡眠质量和强化体能，有助于亚健康状态人群的调理和营养平衡，有助于保持血脂、血压正常，利于护肤养颜，能预防大脑早衰，防止和缓解某些人体器官机能障碍。
本实用发明的有益效果是：
本发明采用湿法粉碎对果渣进行粉碎，解决了果渣干燥困难的问题，省时省力，操作简单；采用药物提取液，更加安全，最大限度了保留了原料中的的活性成分的含量和活性；
本发明结合御米油、火麻油和富硒果渣可以有效的治疗高血压症状，且安全无毒副作用。
具体实施方式
实施例1
一种治疗高血压的口服液，由以下质量成分组成：御米油87g，火麻油10g，富硒果渣2g，蜂蜜1g，木糖醇适量。
富硒果渣制备方法：富硒蓝莓果渣22份、富硒蔓越莓果渣12份、富硒山竹果渣18份、加入到粉碎机中，然后加入药物提取液，药物提取液与混合果渣的重量比为2:1，然后进行湿法超微粉碎，粉碎时间10-20分钟，转速12000rpm，物料粒度下降到200微米以下；然后对果渣浆进行真空浓缩。
药物提取液的制备方法为：提取液是由葛根、丹参、枸杞、三七、百合以及黄芪按照质量比3：2：2：4：2：1复配。将提取物的原料药加入10倍的水，浸泡2小时，煮沸后保持沸腾状态20分钟，经过100-200目筛过滤得滤液；将残渣再加入6倍的水，煮沸后保持沸腾状态30分钟，经100-200目筛过滤得滤液，将两次滤液合并，真空浓缩至原来的1/2，冷却后得到药物提取液。
口服液制备方法：将御米油、火麻油、富硒果渣、蜂蜜和木糖醇放入容器内充分搅拌混合，搅拌器转数为 400r/min，然后加入木糖醇，得混合药液；用氢氧化钠溶液调节 pH值至6.8，再灌封至钠钙玻璃管制口服液瓶中，灌装轧盖后置于98℃条件，灭菌15min，入库即为成品，即得治疗高血压的口服液。
实施例2
一种治疗高血压的口服液，由以下质量成分组成：御米油75g，火麻油5g，富硒果渣1g，蜂蜜1g，木糖醇适量。
富硒果渣制备方法：富硒蓝莓果渣20份、富硒蔓越莓果渣10份、富硒山竹果渣15份加入到粉碎机中，然后加入药物提取液，药物提取液与混合果渣的重量比为2:1，然后进行湿法超微粉碎，粉碎时间10-20分钟，转速12000rpm，物料粒度下降到200微米以下；然后对果渣浆进行真空浓缩。
药物提取液的制备方法为：提取液是由葛根、丹参、枸杞、三七、百合以及黄芪按照质量比3：2：2：4：2：1复配。将提取物的原料药加入10倍的水，浸泡2小时，煮沸后保持沸腾状态20分钟，经过100-200目筛过滤得滤液；将残渣再加入6倍的水，煮沸后保持沸腾状态30分钟，经100-200目筛过滤得滤液，将两次滤液合并，真空浓缩至原来的1/2，冷却后得到药物提取液。
口服液制备方法：将御米油、火麻油、富硒果渣、蜂蜜和木糖醇放入容器内充分搅拌混合，搅拌器转数为 400r/min，然后加入木糖醇，得混合药液；用氢氧化钠溶液调节 pH值至6.8，再灌封至钠钙玻璃管制口服液瓶中，灌装轧盖后置于98℃条件，灭菌15min，入库即为成品，即得治疗高血压的口服液。
实施例3
一种治疗高血压的口服液，由以下质量成分组成：御米油100g，火麻油15g，富硒果渣8g，蜂蜜5g，木糖醇适量。
富硒果渣制备方法：将富硒蓝莓果渣25份、富硒蔓越莓果渣15份、富硒山竹果渣20份加入到粉碎机中，然后加入药物提取液，药物提取液与混合果渣的重量比为2:1，然后进行湿法超微粉碎，粉碎时间10-20分钟，转速12000rpm，物料粒度下降到200微米以下；然后对果渣浆进行真空浓缩。
药物提取液的制备方法为：提取液是由葛根、丹参、枸杞、三七、百合以及黄芪按照质量比3：2：2：4：2：1复配。将提取物的原料药加入10倍的水，浸泡2小时，煮沸后保持沸腾状态20分钟，经过100-200目筛过滤得滤液；将残渣再加入6倍的水，煮沸后保持沸腾状态30分钟，经100-200目筛过滤得滤液，将两次滤液合并，真空浓缩至原来的1/2，冷却后得到药物提取液。
口服液制备方法：将御米油、火麻油、富硒果渣、蜂蜜和木糖醇放入容器内充分搅拌混合，搅拌器转数为 400r/min，然后加入木糖醇，得混合药液；用氢氧化钠溶液调节 pH值至6.8，再灌封至钠钙玻璃管制口服液瓶中，灌装轧盖后置于98℃条件，灭菌15min，入库即为成品，即得治疗高血压的口服液。
对比例1
一种治疗高血压的口服液，由以下质量成分组成：御米油60g，火麻油3g，富硒果渣10g，蜂蜜6g，木糖醇适量，富硒蓝莓果渣25份、富硒蔓越莓果渣15份、富硒山竹果渣20份。
口服液制备方法：将御米油、火麻油、富硒果渣、蜂蜜和木糖醇放入容器内充分搅拌混合，搅拌器转数为 400r/min，然后加入木糖醇，得混合药液；用氢氧化钠溶液调节 pH值至6.8，再灌封至钠钙玻璃管制口服液瓶中，灌装轧盖后置于98℃条件，灭菌15min，入库即为成品，即得治疗高血压的口服液。
药物毒理学试验
1、急性毒性试验
以本发明实施例1制得的颗粒剂为试验，采用灌胃给药方式，在24h内连续给药2次，每次间隔大于4h，每次给药50生药量，累积药物总量达100g生药/kg，相当于人临床用量的50倍。 给药后7d内，小鼠活动、进食、排泄均正常，生长良好，毛色光亮，其平均体重均随实验时间的延长而增加。第8d处死后解剖每只小鼠，肉眼观察心、肝、脾、肺、肾、脑、胸腺、胃、肠等均 未发现颜色及形态异常，未能测出半数致死量（LD50）。结果表明：本发明中药无急性毒性反应。
2、长期毒性试验
以本发明实施例1制得的颗粒剂为试验，采用灌胃给药方式，将本发明中药分为低剂量、中剂量、高剂量三组，各组的药物用量分别为10、30、50g生药/kg/d，相当于临床剂量的10、30、50倍。灌胃给药24周后，本发明中药对动物的一般状况、血液学指标、血液生化指标均无明显的影响，系统解剖、脏器系数及组织病理学检查也未发现异常病理改变。停药2周也未见明显改变。结果表明：本发明中药在长期毒性试验中，未发现明显毒性反应和延迟毒性反应。可见，本发明中药无毒性反应，长期用药安全可靠。
临床资料：
1.病例选择：
选择确诊的高血压400例临床观察，其中男220例，女性180例，年龄25-65岁，平均年龄34.7岁。将该400例患者随机分为治疗3组、对照1组共四组，每组100例，各组病例的病程、症状轻重程度基本一致，无显著差异，具有可比性。
2、诊断标准
按《内科学》第8版为高血压的诊断标准。
3、治疗方法
治疗1-3组：分别服用本发明实施例1-3制备的口服液，每日两次，早、晚各一次，饭后半小时服用，每次服用相当于20g生药量的剂量。7天为一个疗程。
对照1组：服用本发明对比例1制备的口服液，每日两次，早、晚各一次，饭后半小时服用，每次服用相当于20g生药量的剂量。7天为一个疗程。
4、疗效评价标准
参照《中医病证诊断疗效标准》进行疗效评价。
治愈：症状、体征及有关实验室检查基本正常；
好转：症状及体征减轻，实验室检查有改善；
未愈：症状无改变。
5、治疗结果
表1两组治疗前后症状改善情况比较
经过一个月的治疗后，各组的疗效如表1所示：治疗组的治愈率为93-97%，与对照组相比，治疗组的治愈率和总有效率均远远优于对照组，差异有统计学意义（P＜0.05），说明本发明中药中各组分有明显的协同增效作用。
根据上述表格中数据可知，本发明中药具有起效快、有效率高、疗效确切、安全性高、无毒副作用、用药简单的优势；同时，根据临床观察、常规化验及功能检测均未发现异常，且随访1年，结果统计，治疗组无复发，而对照组70例治愈患者，复发5例，复发率7.14%。
6、典型病例
案例一，李某，男，55岁，诊断为高血压，面色红胀，头痛，耳鸣，失眠，服用了本药治疗，1个月后，症状全部消失，随访至今未再复发。
案例二，王某，女，69岁，患有严重高血压，并伴有肢体麻木，失眠，服用本药治疗，4周后病情好转，2个月后治疗效果较为明显，6个月后，症状基本消失，继续服用本药巩固2年，身体调理正常，至今身体很好，无复发。
案例三，张某，60岁，女，体倦乏力、头痛头晕，并伴有记忆力减退，行动不便，服用了本药治疗，6个月后，经检查，血压正常，心脏跳动均匀有力，至今无复发。
案例四，刘某，男，66岁，诊断为高血压，面色红胀，头痛，耳鸣，失眠，服用本药治疗，治疗一个月后，血压降低且稳定，身体逐渐好转，到目前没有复发。
显然，本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样，倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内，则本发明也意图包含这些改动和变型在内。
Claims (7)
1.一种治疗高血压的口服液，其特征在于，由以下成分组成：御米油75-100g，火麻油5-15g，富硒果渣1-8g，蜂蜜1-5g，木糖醇适量。
2.如权利要求1所述的治疗高血压的口服液，其特征在于，御米油87g，火麻油10g，富硒果渣2g，蜂蜜1g，木糖醇适量。
3.如权利要求1或2所述的治疗高血压的口服液，其特征在于，所述富硒果渣是由富硒蓝莓果渣20-25份、富硒蔓越莓果渣10-15份、富硒山竹果渣15-20份制备而成。
4.如权利要求1或2所述的治疗高血压的口服液，其特征在于，所述的富硒果渣的制备方法：将富硒蓝莓、富硒蔓越莓、富硒山竹果渣加入到粉碎机中，然后加入药物提取液，药物提取液与混合果渣的重量比为2:1，然后进行湿法超微粉碎，粉碎时间10-20分钟，转速12000rpm，物料粒度下降到200微米以下；然后对果渣浆进行真空浓缩。
5.如权利要求4所述的治疗高血压的口服液，其特征在于，所述的药物提取液的制备方法为：提取液是由葛根、丹参、枸杞、三七、百合以及黄芪按照质量比3：2：2：4：2：1复配后水提而成。
6.如权利要求4所述的治疗高血压的口服液，其特征在于，药物提取液的制备方法为：将提取物的原料药加入10倍的水，浸泡2小时，煮沸后保持沸腾状态20分钟，经过100-200目筛过滤得滤液；将残渣再加入6倍的水，煮沸后保持沸腾状态30分钟，经100-200目筛过滤得滤液，将两次滤液合并，真空浓缩至原来的1/2，冷却后得到药物提取液。
7.如权利要求1或2所述的治疗高血压的口服液的制备方法，其特征在于，将御米油、火麻油、富硒果渣、蜂蜜和木糖醇放入容器内充分搅拌混合，搅拌器转数为 400r/min，然后加入木糖醇，得混合药液；用氢氧化钠溶液调节 pH值至6.8，再灌封至钠钙玻璃管制口服液瓶中，灌装轧盖后置于98℃条件，灭菌15min，入库即为成品，即得治疗高血压的口服液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811365006.3A CN109464587A (zh) | 2018-11-16 | 2018-11-16 | 一种治疗高血压的口服液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811365006.3A CN109464587A (zh) | 2018-11-16 | 2018-11-16 | 一种治疗高血压的口服液 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109464587A true CN109464587A (zh) | 2019-03-15 |
Family
ID=65673836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811365006.3A Withdrawn CN109464587A (zh) | 2018-11-16 | 2018-11-16 | 一种治疗高血压的口服液 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109464587A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110101742A (zh) * | 2019-03-08 | 2019-08-09 | 北京梅尔森医药技术开发有限公司 | 一种火麻油蜂蜜的组合物及其制备方法和应用 |
| CN110179916A (zh) * | 2019-07-16 | 2019-08-30 | 哈尔滨膳宝酒业有限公司 | 一种亚麻籽油牛蒡制成的降血脂、降血糖中药口服液 |
| CN110585361A (zh) * | 2019-10-22 | 2019-12-20 | 哈尔滨映日生物医药科技有限责任公司 | 一种麦冬炙甘草益气复脉、养阴生津的中药袋泡茶 |
-
2018
- 2018-11-16 CN CN201811365006.3A patent/CN109464587A/zh not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110101742A (zh) * | 2019-03-08 | 2019-08-09 | 北京梅尔森医药技术开发有限公司 | 一种火麻油蜂蜜的组合物及其制备方法和应用 |
| CN110179916A (zh) * | 2019-07-16 | 2019-08-30 | 哈尔滨膳宝酒业有限公司 | 一种亚麻籽油牛蒡制成的降血脂、降血糖中药口服液 |
| CN110585361A (zh) * | 2019-10-22 | 2019-12-20 | 哈尔滨映日生物医药科技有限责任公司 | 一种麦冬炙甘草益气复脉、养阴生津的中药袋泡茶 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103141709B (zh) | 一种鲤鱼饲料及其制备方法 | |
| CN102613555B (zh) | 一种玛咖粉人参组合物及其制备方法 | |
| CN109464587A (zh) | 一种治疗高血压的口服液 | |
| CN105124347A (zh) | 一种辣木降血糖组合物及其制备方法 | |
| CN115317574A (zh) | 一种用于治疗高尿酸血症的组合物及其应用 | |
| CN105925421A (zh) | 一种防治更年期综合征的金花葵保健酒及其制备方法 | |
| JP2018510641A (ja) | 発毛促進、脱毛緩和及び改善、血糖調節、胃腸障害の症状緩和及び改善用健康補助食品 | |
| CN108837085A (zh) | 一种排毒胶囊及其制备方法 | |
| KR101512230B1 (ko) | 면역력 및 혈액순환 개선 기능을 갖는 관절염 치료 조성물과 그 제조방법 | |
| CN100500174C (zh) | 一种用于降血糖的药物组合物及其制备方法和用途 | |
| CN103720808B (zh) | 一种具有通便功效的组合物及其用途、制备方法 | |
| CN113925172A (zh) | 一种适用于儿童的大鲵肽营养组合物 | |
| CN102973726B (zh) | 一种用于高血压的中成药 | |
| CN106036834A (zh) | 一种含青梅的具有改善睡眠功效的保健食品组合物 | |
| CN108056461B (zh) | 一种黑木耳润肠功能咀嚼片及其制备方法 | |
| CN110384782A (zh) | 一种干预痰湿体质的中药组合物、破壁组合物及其制备方法 | |
| CN103798475B (zh) | 改善围绝经期亚健康状态的中草药蜜茶(无糖颗粒)及制备工艺 | |
| CN108938718A (zh) | 一种用于治疗脑中风的中药组合物及其制剂的制备方法 | |
| CN106975023A (zh) | 一种牛口服补液盐及其制备方法 | |
| CN1299755C (zh) | 一种肉桂复方药物及其制备方法和应用 | |
| CN105998536A (zh) | 一种玛咖片及其制备方法 | |
| CN107837309B (zh) | 一种具有辅助降血糖功能的组合物及其制备方法 | |
| CN105902884A (zh) | 一种含青梅的辅助降血糖的保健食品组合物及其制备方法 | |
| CN109692277A (zh) | 一种治疗糖尿病的中草药制剂 | |
| WO2004089388A1 (fr) | Medicament chinois pret a l'emploi pour le traitement de la perte des cheveux et son procede de fabrication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190315 |
|
| WW01 | Invention patent application withdrawn after publication |